Advances in antifungal therapy.
The prevalence of invasive fungal infections (IFIs) has increased over the past three decades owing to the increasing numbers of immunocompromised hosts. These infections are associated with significant morbidity and mortality. Recent significant advances in antifungal therapy include the broad-spectrum triazoles (voriconazole and posaconazole) and a new class of antifungals, the echinocandins (caspofungin, micafungin, and anidulafungin). New treatment strategies, such as combination therapy and pre-emptive therapy, are being investigated. There have also been significant improvements in diagnostics; the galactomannan enzyme immunoassay and the beta-glucan test are now part of the EORTC/MSG criteria for diagnosis of IFI. Despite these advances, there remain a number of unanswered questions regarding optimal management of serious fungal infections, and research continues to discover and develop new therapies and evaluate new management strategies.
Sable
Carole A
CA
Novexel SA, Romainville, France. carole.sable@novexel.com
Strohmaier
Kim M
KM
Chodakewitz
Jeffrey A
JA
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D054714:Echinocandins / Q000627:therapeutic use; D006801:Humans; D009181:Mycoses / Q000175:diagnosis* / Q000188:drug therapy*; D014230:Triazoles / Q000627:therapeutic use
D000935:Antifungal Agents; D054714:Echinocandins; D014230:Triazoles